Javascript must be enabled to continue!
Reducing environmental impact and costs in dentistry: replacing theatre gowns with aprons to support NHS Net Zero goals
View through CrossRef
Abstract
Background
This sustainability and quality improvement project aimed to reduce the environmental burden and financial cost of personal protective equipment (PPE) used in the Oral and Maxillofacial Surgery (OMFS) department at Mid Yorkshire Teaching NHS Trust. Specifically, it evaluated the impact of replacing single-use gowns with disposable aprons for dentoalveolar procedures under local anaesthetic (LA) carried out in theatres.
Methods
The AQUA Theatreman system was used to identify all LA dentoalveolar theatre procedures between 1 January and 31 December 2024. PPE use was calculated assuming three scrubbed staff per case. Carbon footprint data were taken from published estimates (905 g CO2e per gown; 65 g CO2e per apron). Cost information was obtained from the Trust. Following approval, a standard operating procedure allowing apron use was introduced in February 2025.
Results
A total of 613 LA cases were assessed, equating to 1839 gowns. This generated 1664 kg CO2e and cost £2979.18. Equivalent apron use would produce 358 kg CO2e and cost £36.78, saving 1306 kg CO2e and £2942.40. Patients also, anecdotally, reported reduced anxiety with apron use.
Conclusion
Replacing gowns with aprons substantially decreases environmental impact and financial costs while improving patient experience, supporting the NHS Net Zero agenda and offering a scalable sustainability intervention.
Title: Reducing environmental impact and costs in dentistry: replacing theatre gowns with aprons to support NHS Net Zero goals
Description:
Abstract
Background
This sustainability and quality improvement project aimed to reduce the environmental burden and financial cost of personal protective equipment (PPE) used in the Oral and Maxillofacial Surgery (OMFS) department at Mid Yorkshire Teaching NHS Trust.
Specifically, it evaluated the impact of replacing single-use gowns with disposable aprons for dentoalveolar procedures under local anaesthetic (LA) carried out in theatres.
Methods
The AQUA Theatreman system was used to identify all LA dentoalveolar theatre procedures between 1 January and 31 December 2024.
PPE use was calculated assuming three scrubbed staff per case.
Carbon footprint data were taken from published estimates (905 g CO2e per gown; 65 g CO2e per apron).
Cost information was obtained from the Trust.
Following approval, a standard operating procedure allowing apron use was introduced in February 2025.
Results
A total of 613 LA cases were assessed, equating to 1839 gowns.
This generated 1664 kg CO2e and cost £2979.
18.
Equivalent apron use would produce 358 kg CO2e and cost £36.
78, saving 1306 kg CO2e and £2942.
40.
Patients also, anecdotally, reported reduced anxiety with apron use.
Conclusion
Replacing gowns with aprons substantially decreases environmental impact and financial costs while improving patient experience, supporting the NHS Net Zero agenda and offering a scalable sustainability intervention.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
A New Approach to Surgical Gowns
A New Approach to Surgical Gowns
Emerging diseases such as Ebola hemorrhagic fever, hepatitis B, hepatitis C, SARS, and most recently the Covid 19 epidemic have increased the importance of hygiene in the world, br...
Perceptions of anonymised data use and awareness of the NHS data opt-out amongst patients, carers and healthcare staff
Perceptions of anonymised data use and awareness of the NHS data opt-out amongst patients, carers and healthcare staff
Abstract
Introduction
Public awareness and support for secondary health data use may vary by health care experience and partici...
Method of evaluating and diagnosing costs for event management
Method of evaluating and diagnosing costs for event management
The article develops a method of evaluating and diagnosing costs for event management in the form of a matrix that takes into account the directions of managing event processes of ...
NHS Patient Choice Policy in England: What Mapping the Private Healthcare Market for NHS Patients Can Tell Us
NHS Patient Choice Policy in England: What Mapping the Private Healthcare Market for NHS Patients Can Tell Us
Abstract
This article examines how the private healthcare market supports successive governments’ commitment in the English National Health Service (NHS) to patient choic...

